| P50 | author | Folkert J van Kemenade | Q89556217 |
| | Veerle M. Coupé | Q73190157 |
| P2093 | author name string | J. Berkhof | |
| | P. J. Snijders | |
| | R. H. Verheijen | |
| | W. Verweij | |
| | L. Rozendaal | |
| | D. C. Rijkaart | |
| | D. A M. Heideman | |
| | A. T. Hesselink | |
| | C. J L M. Meijer | |
| P2860 | cites work | The causal relation between human papillomavirus and cervical cancer | Q24673148 |
| | Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 |
| | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| | Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 |
| | Interval Estimation for a Binomial Proportion | Q29010600 |
| | Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 |
| | Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 |
| | Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months | Q79926062 |
| | Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 |
| | Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial | Q82586477 |
| | Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial | Q83938901 |
| | How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands | Q84147482 |
| | Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis | Q33233738 |
| | Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial | Q33518244 |
| | Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. | Q33923869 |
| | Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral | Q34153160 |
| | Assessment of diagnostic tests when disease verification is subject to selection bias | Q34272301 |
| | Human papillomavirus and Papanicolaou tests to screen for cervical cancer | Q34702284 |
| | Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools | Q34783310 |
| | Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination | Q34997604 |
| | Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program | Q35073445 |
| | The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. | Q35587534 |
| | Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening | Q35644704 |
| | Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination | Q36537615 |
| | Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses | Q36584432 |
| | Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting | Q36615447 |
| | Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women | Q36622396 |
| | Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. | Q37265745 |
| | Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries | Q37291430 |
| | Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older | Q37461977 |
| | Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. | Q39815478 |
| | Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. | Q39979527 |
| | Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years | Q43452461 |
| | Cervical screening according to age and HPV status | Q44458983 |
| | Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring | Q44574224 |
| | Human papillomavirus DNA testing for cervical cancer screening in low-resource settings | Q44798289 |
| | Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening | Q44876752 |
| | The health and economic effects of HPV DNA screening in The Netherlands | Q45496797 |
| | Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening | Q46570221 |
| | Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). | Q51794674 |
| | HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. | Q51824401 |
| | Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. | Q53028990 |
| | Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. | Q53304855 |
| | Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. | Q53322866 |
| | Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. | Q53360347 |
| | Trends in Cervical Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of Screening | Q57027360 |
| | Overview of the European and North American studies on HPV testing in primary cervical cancer screening | Q57414808 |
| | HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica | Q73347438 |
| | High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy | Q73824709 |
| | Comparing disease screening tests when true disease status is ascertained only for screen positives | Q73838373 |
| | Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial | Q79824170 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| | nucleic acid hybridization | Q8223839 |
| P304 | page(s) | 939-946 | |
| P577 | publication date | 2010-08-31 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test | |
| P478 | volume | 103 | |